2018
Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis
Lim JK, Liapakis AM, Shiffman ML, Lok AS, Zeuzem S, Terrault NA, Park JS, Landis CS, Hassan M, Gallant J, Kuo A, Pockros PJ, Vainorius M, Akushevich L, Michael L, Fried MW, Nelson DR, Ben-Ari Z, Group H. Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis. Clinical Gastroenterology And Hepatology 2018, 16: 1811-1819.e4. PMID: 29306043, PMCID: PMC6034985, DOI: 10.1016/j.cgh.2017.12.037.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntiviral AgentsBenzimidazolesDrug Therapy, CombinationDrug-Related Side Effects and Adverse ReactionsEuropeFemaleFluorenesGenotypeHepacivirusHepatitis C, ChronicHumansLiver CirrhosisLongitudinal StudiesMaleMiddle AgedNorth AmericaProspective StudiesRibavirinSofosbuvirSustained Virologic ResponseTreatment OutcomeYoung AdultConceptsTreatment-experienced patientsGenotype 1 HCV infectionAddition of ribavirinHCV infectionGenotype 1 hepatitis C virus infectionChronic genotype 1 HCV infectionHepatitis C virus infectionHCV-TARGET studyRate of SVR12Treatment-experienced adultsC virus infectionPrimary efficacy endpointGenotype 1 infectionObservational cohort studyWeeks of treatmentEnd of treatmentRoutine clinical practiceSofosbuvir treatmentVirologic outcomesVirologic responseEfficacy endpointHepatitis CProtocol populationAdverse eventsCohort study
2009
Management and Treatment of Patients With Cirrhosis and Portal Hypertension: Recommendations From the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program
Garcia-Tsao G, Lim J. Management and Treatment of Patients With Cirrhosis and Portal Hypertension: Recommendations From the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. The American Journal Of Gastroenterology 2009, 104: 1802. PMID: 19455106, DOI: 10.1038/ajg.2009.191.Peer-Reviewed Original ResearchMeSH KeywordsCause of DeathDiagnostic ImagingDisease ProgressionEvidence-Based MedicineFemaleGastrointestinal HemorrhageHepatitis C, ChronicHepatorenal SyndromeHumansHypertension, PortalImmunohistochemistryLiver CirrhosisLiver FailureLiver Function TestsMaleRandomized Controlled Trials as TopicRisk AssessmentSeverity of Illness IndexSurvival AnalysisUnited StatesUnited States Department of Veterans AffairsConceptsVariceal hemorrhageSevere complicationsHepatocellular carcinomaAcute variceal hemorrhageComplications of cirrhosisPresence of ascitesChronic liver diseaseSpontaneous bacterial peritonitisTreatment of ascitesRandomized clinical trialsTreatment of patientsStratification of patientsDifferent risk groupsQuality of lifeDecompensated patientsHepatorenal syndromeHepatitis CPortal hypertensionCirrhotic patientsProspective trialBacterial peritonitisHemodynamic alterationsLiver diseaseTreatment adherenceAscites formation